Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Congress 2022 | The role of interferon in polycythemia vera & perspectives on the management of low-risk patients

Richard Silver • 18 Oct 2022
MPN Congress 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Interferon Ropeginterferon alfa-2b

Richard Silver, MD, Weill Cornell Medical College, New York, NY, comments on the efficacy of interferon (IFN) in comparison to hydroxyurea and phlebotomy in the treatment of patients with low-risk polycythemia vera (PV), explaining the mechanism of action of IFN and highlighting data from several studies. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Richard Silver

Interferon in polycythemia vera: long - term experience from a single center
Richard Silver • 10 Nov 2022
3:23
The role of rusfertide in polycythemia vera
Richard Silver • 18 Oct 2022
6:19
Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF
Richard Silver • 18 Oct 2022
2:50
Looking forward to the 2022 MPN Congress
Richard Silver • 18 Oct 2022

Related Videos

2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024
1:07
Key advancements in the treatment of BPDCN from EBMT 2024
Cristina Papayannidis • 22 Apr 2024
1:27
First-line tagraxofusp followed by alloSCT in BPDCN: a case study
Cristina Papayannidis • 22 Apr 2024
2:03
Current SoC for BPDCN and other emerging treatment options
Cristina Papayannidis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals